When was Syntax Bio founded?

Syntax Bio was founded in 2018 and raised its 1st funding round 8 years after it was founded.

Where is Syntax Bio located?

Syntax Bio is headquartered in Chicago, United States.

How many employees does Syntax Bio have?

As of May 31, 2026, the latest employee count at Syntax Bio is 13.

Is Syntax Bio a funded company?

Syntax Bio is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Jun 22, 2026.

When was the latest funding round of Syntax Bio?

Syntax Bio's latest funding was a $***** Series A round on Jun 22, 2026, with participation from 14 investors.

Where does Syntax Bio rank among its competitors?

Syntax Bio ranks 11th amongst 90 active competitors, of which 12 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Genoskin, which secured $5.4M in Sep, 2025.

Who are the top competitors of Syntax Bio?

Syntax Bio's top competitors include Genoskin, Cayman Chem and PhenoVista. Among them, Syntax Bio secured the most recent funding round in June, 2026.

Syntax Bio - 2026 Company Profile, Funding & Competitors

Company Details

Syntax Bio is a preclinical-stage biotechnology company focused on advancing stem cell-derived therapies. The company utilizes a modified CRISPR system to direct stem cells to become a desired cell type, enhancing scalability and efficiency in cell therapy manufacturing. With its innovative technology platform, Syntax Bio aims to overcome longstanding challenges in stem cell-derived therapies and unlock new possibilities for treating various diseases.

Key Metrics

Founded Year

2018

Location

Chicago, United States

Stage

Series A

Total Funding

$25M in 1 round

Latest Funding Round

Series A, Jun 22, 2026, $*****

Ranked

11^th among 90 active competitors

Employee Count

13 as on May 31, 2026

Similar Companies

Genoskin & 99 more

View Syntax Bio's full profile

Syntax Bio has raised a total funding of $25M over 1 round. Its latest funding round was a Series A round on Jun 22, 2026 for $*****. 14 investors participated in its latest round.

Here is the list of recent funding rounds of Syntax Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 22, 2026	8306541	Series A	3777891	9347159	5165792	9872608

Access funding benchmarks and valuations. Sign up today!

View details of Syntax Bio's funding rounds and investors

Syntax Bio's employee count trend

Syntax Bio has 13 employees as of May 26. Here is Syntax Bio's employee count trend over the years:

Uncover Syntax Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Syntax Bio include Genoskin, Cayman Chem and PhenoVista. Here is the list of Top 10 competitors of Syntax Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Genoskin 2011, Toulouse (France), Series A	In vitro human skin models for preclinical toxicity and efficacy testing	$5.4M	OCCTE, Bpifrance & 7 others	54/100
2nd	Cayman Chem 1980, Ann Arbor (United States), Funding Raised	Develops bioreagents and offers preclinical services	-	Tehnopol Startup Incubator, Broadoak Capital Partners ... & 2 others	50/100
3rd	PhenoVista 2014, San Diego (United States), Acquired	High-content imaging and analysis services to accelerate drug discovery	$3M	Fujifilm, Broadoak Capital Partners & 1 others	47/100
4th	Magnitude Biosciences 2018, Durham (United Kingdom), Seed	Provider of cell-free in vitro assay for drug discovery companies	$2.6M	Northstar Ventures, Saker Capital & 10 others	46/100
5th	Reaction Biology 2001, United States, Late Stage	In vitro enzyme activity assays, secializing in kinase & epigenetic HTS and profiling	-	Cobepa, CYwP Funds & 6 others	40/100
6th	Quantumcyte 2013, Sunnyvale (United States), Seed	Drug assay system to treat cancer	$1.3M	IndieBio, Bayes Ventures	40/100
7th	Radiant Research Services 2009, Bengaluru (India), Acquired	Preclinical in vitro testing and development services	-	-	39/100
8th	Discovery Biomed 2007, Birmingham (United Kingdom), Acquired	Contract research organization	-	NIDDK, Greer Capital Advisors & 4 others	39/100
9th	Orient Gene Biotech 2005, China, Unfunded	Manufactrurer and R&D of in vitro diagnostic reagents	-	-	38/100
10th	Leadgene Biomedical 2013, Tainan (Taiwan), Unfunded	CRO offers invitro drug testing services	-	-	36/100
11th	Syntax Bio 2018, Chicago (United States), Series A	Preclinical-stage biotech company that develops innovative stem cell-derived therapies by leveraging CRISPR technology	$25M	-	46/100